LifeSci Capital upgraded InflaRx to Outperform from Market Perform after Gohibic received FDA Emergency Use Authorization for the treatment of critically ill COVID-19 patients, calling the news "an upside surprise to us and the vast majority of investors." The firm says it plans to do more work on the potential market opportunity for Gohibic in COVID-19, but believes that "the drug has a nice position within the market based on its label," adding that there is still a "notable market opportunity" for novel COVID-19 therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IFRX:
- InflaRx (NASDAQ:IFRX) Stock Spikes: Is There Further Upside?
- InflaRx up 47% after receiving EUA for Gohibic use in COVID-19 treatment
- InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
- InflaRx announces Gohibic receives FDA Emergency Use Authorization
- InflaRx reports FY22 EPS (EUR0.67) vs EUR 1.10 last year